Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial

Rong Zheng, Congfei Wang, Xiaoxue Huang, Qingliang Lin, Daxin Huang, Xiao-Bo Li, Heguang Huang, Benhua Xu, Rong Zheng, Congfei Wang, Xiaoxue Huang, Qingliang Lin, Daxin Huang, Xiao-Bo Li, Heguang Huang, Benhua Xu

Abstract

Introduction: The question of how to administer adequate chemotherapy to synchronise stereotactic body radiation therapy (SBRT) treatment strategy to maximise the benefits of neoadjuvant therapy for the improved prognosis of patients with borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer is a challenging and debatable issue. No studies have yet evaluated the efficacy of split-course SBRT as the neoadjuvant chemoradiotherapy regimen. We aimed to study whether neoadjuvant chemotherapy plus split-course SBRT results in better outcomes in BRPC and LAPC patients.

Methods and analysis: Treatment-naïve patients with radiographically confirmed BRPC or LAPC, supporting biopsy results and no severe comorbidities will be enrolled. They will be treated with nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT, followed by an investigator's choice of continuation of treatment with nab-P+Gem or surgery. nab-P+Gem chemotherapy will commence on day 1 for each of six cycles: nab-paclitaxel 125 mg/m2 intravenous infusion over approximately 30-45 min, followed by gemcitabine 1000 mg/m2 intravenous infusion over about 30 min on days 1 and 15 of each 28-day cycle. During the first and second cycles of chemotherapy, SBRT will be given as a single irradiation of 10 Gy four times (days 2 and 16 of each 28-day cycle). The primary endpoint is progression-free survival; while the secondary outcomes are the time to treatment failure, disease control rate, overall response rate, overall survival, R0 resection rate and incidence of adverse effects.

Ethics and dissemination: The study protocol was approved by the Ethics Committee of Xiehe Affiliated Hospital of Fujian Medical University (No. 2019YF015-01). Results from our study will be disseminated in international peer-reviewed journals. All study procedures were developed in order to assure data protection and confidentiality.

Trial registration number: NCT04289792.

Keywords: chemotherapy; pancreatic disease; radiation oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Overall study design. CR, complete response; CT, computed tomography; IV, intravenous; MRI, magnetic resonance imaging; PD, progressive disease; PET, positron emission tomography; PR, partial response; SD, stable disease.
Figure 2
Figure 2
Neoadjuvant chemoradiotherapy design. nab-P+Gem, nab-paclitaxel plus gemcitabine; SBRT, stereotactic body radiation therapy.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30. 10.3322/caac.21387
    1. Chen W, Zheng R, Baade PD, et al. . Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32. 10.3322/caac.21338
    1. Saif MW. Pancreatic neoplasm in 2011: an update. JOP 2011;12:316–21.
    1. Oettle H, Neuhaus P, Hochhaus A, et al. . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473–81. 10.1001/jama.2013.279201
    1. Regine WF, Winter KA, Abrams R, et al. . Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011;18:1319–26. 10.1245/s10434-011-1630-6
    1. Michelakos T, Pergolini I, Castillo CF-del, et al. . Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with Folfirinox. Ann Surg 2019;269:733–40. 10.1097/SLA.0000000000002600
    1. Gao S, Zhu X, Shi X, et al. . Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol 2019;14:52. 10.1186/s13014-019-1254-8
    1. Zhong J, Patel K, Switchenko J, et al. . Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 2017;123:3486–93. 10.1002/cncr.30706
    1. Mellon EA, Hoffe SE, Springett GM, et al. . Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015;54:979–85. 10.3109/0284186X.2015.1004367
    1. Chuong MD, Springett GM, Weber J, et al. . Induction gemcitabine-based chemotherapy and neoadjuvant stereotactic body radiation therapy achieve high margin-negative resection rates for borderline resectable pancreatic cancer. J Radiat Oncol 2012;1:273–81. 10.1007/s13566-012-0039-6
    1. Polistina F, Costantin G, Casamassima F, et al. . Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010;17:2092–101. 10.1245/s10434-010-1019-y
    1. Rombouts SJ, Walma MS, Vogel JA, et al. . Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol 2016;23:4352–60. 10.1245/s10434-016-5373-2
    1. Moningi S, Dholakia AS, Raman SP, et al. . The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol 2015;22:2352–8. 10.1245/s10434-014-4274-5
    1. Herman JM, Chang DT, Goodman KA, et al. . Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:1128–37. 10.1002/cncr.29161
    1. Kharofa J, Mierzwa M, Olowokure O, et al. . Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer. Am J Clin Oncol 2019;42:247–52. 10.1097/COC.0000000000000518
    1. Shaib WL, Hawk N, Cassidy RJ, et al. . A phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified Folfirinox (NCT01446458). Int J Radiat Oncol Biol Phys 2016;96:296–303. 10.1016/j.ijrobp.2016.05.010
    1. Bae SH, Kim M-S, Kim SY, et al. . Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies. Int J Colorectal Dis 2013;28:1707–13. 10.1007/s00384-013-1717-6
    1. Rostom AY, Tahir S, Gershuny AR, et al. . Once weekly irradiation for carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1996;35:289–92. 10.1016/0360-3016(96)00063-6
    1. McLaren DB, Morrey D, Mason MD. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol 1997;43:171–4. 10.1016/S0167-8140(97)01943-9
    1. Scholten AN, Leer JW, Collins CD, et al. . Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol 1997;43:163–9. 10.1016/S0167-8140(96)01893-2
    1. Jose CC, Price A, Norman A, et al. . Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin Oncol 1999;11:330–3. 10.1053/clon.1999.9075
    1. Hafeez S, McDonald F, Lalondrelle S, et al. . Clinical outcomes of image guided adaptive Hypofractionated Weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys 2017;98:115–22. 10.1016/j.ijrobp.2017.01.239
    1. Bledsoe TJ, Noble AR, Reddy CA, et al. . Split-course accelerated Hypofractionated radiotherapy (SCAHRT): a safe and effective option for head and neck cancer in the elderly or infirm. Anticancer Res 2016;36:933–9.
    1. Suker M, Beumer BR, Sadot E, et al. . Folfirinox for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016;17:801–10. 10.1016/S1470-2045(16)00172-8
    1. Muranaka T, Kuwatani M, Komatsu Y, et al. . Comparison of efficacy and toxicity of folfirinox and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol 2017;8:566–71. 10.21037/jgo.2017.02.02
    1. Verma V, Lazenby AJ, Zheng D, et al. . Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: secondary analysis of a prospective clinical trial. Radiother Oncol 2017;122:464–9. 10.1016/j.radonc.2016.12.030
    1. Benedict SH, Yenice KM, Followill D, et al. . Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 2010;37:4078–101. 10.1118/1.3438081
    1. Blomstrand H, Scheibling U, Bratthäll C, et al. . Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 2019;19:40. 10.1186/s12885-018-5244-2
    1. Kokkali S, Tripodaki E-S, Drizou M, et al. . Biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer. In Vivo 2018;32:653–7. 10.21873/invivo.11289
    1. Ahn DH, Krishna K, Blazer M, et al. . A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol 2017;9:75–82. 10.1177/1758834016676011
    1. Gemenetzis G, Groot VP, Blair AB, et al. . Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 2019;270:340–7. 10.1097/SLA.0000000000002753
    1. Jang J-Y, Han Y, Lee H, et al. . Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 2018;268:215–22. 10.1097/SLA.0000000000002705
    1. Bednar F, Zenati MS, Steve J, et al. . Analysis of predictors of resection and survival in locally advanced stage III pancreatic cancer: does the nature of chemotherapy regimen influence outcomes? Ann Surg Oncol 2017;24:1406–13. 10.1245/s10434-016-5707-0
    1. Rombouts SJ, Walma MS, Vogel JA, et al. . Systematic review of resection rates and clinical outcomes after FOLFIRINOX-ased treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol 2016;23:4352–60. 10.1245/s10434-016-5373-2
    1. Conroy T, Bachet J-B, Ayav A, et al. . Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer 2016;57:10–22. 10.1016/j.ejca.2015.12.026
    1. Murphy JD, Christman-Skieller C, Kim J, et al. . A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2010;78:1420–6. 10.1016/j.ijrobp.2009.09.075
    1. Paik EK, Kim M-S, Seo Y-S, et al. . Feasibility of split-course stereotactic ablative radiotherapy for oligometastases. Jpn J Clin Oncol 2018;48:548–54. 10.1093/jjco/hyy062
    1. Gielda BT, Marsh JC, Zusag TW, et al. . Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol 2011;6:1079–86. 10.1097/JTO.0b013e3182199a7c
    1. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12.
    1. Milas L, Fujii T, Hunter N, et al. . Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107–14.
    1. Higuchi Y, Serizawa T, Nagano O, et al. . Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors. Int J Radiat Oncol Biol Phys 2009;74:1543–8. 10.1016/j.ijrobp.2008.10.035
    1. Hsieh C-H, Chang H-T, Lin S-C, et al. . Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment-case report. BMC Cancer 2010;10:696. 10.1186/1471-2407-10-696
    1. Angelov L, Mohammadi AM, Bennett EE, et al. . Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. J Neurosurg 2018;129:366–82. 10.3171/2017.3.JNS162532
    1. Carlson DJ, Keall PJ, Loo BW, et al. . Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011;79:1188–95. 10.1016/j.ijrobp.2010.10.007
    1. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 RS involved? Int J Radiat Oncol Biol Phys 2014;88:254–62. 10.1016/j.ijrobp.2013.07.022
    1. Park HJ, Griffin RJ, Hui S, et al. . Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012;177:311–27. 10.1667/RR2773.1
    1. Finkelstein SE, Timmerman R, McBride WH, et al. . The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011;2011:p. 439752. 10.1155/2011/439752
    1. Song CW, Kim M-S, Cho LC, et al. . Radiobiological basis of SBRT and SRS. Int J Clin Oncol 2014;19:570–8. 10.1007/s10147-014-0717-z
    1. Filatenkov A, Baker J, Mueller AMS, et al. . Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 2015;21:3727–39. 10.1158/1078-0432.CCR-14-2824
    1. Lee Y, Auh SL, Wang Y, et al. . Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114:589–95. 10.1182/blood-2009-02-206870
    1. Lugade AA, Moran JP, Gerber SA, et al. . Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516–23. 10.4049/jimmunol.174.12.7516
    1. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759–67. 10.1002/ijc.25429
    1. Aryankalayil MJ, Makinde AY, Gameiro SR, et al. . Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res 2014;182:139–48. 10.1667/RR13731.1

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren